FLORBETABEN F-18 - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for florbetaben f-18 and what is the scope of patent protection?
Florbetaben f-18
is the generic ingredient in one branded drug marketed by Life Molecular and is included in one NDA. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.Florbetaben f-18 has thirty-five patent family members in twenty-seven countries.
One supplier is listed for this compound.
Summary for FLORBETABEN F-18
International Patents: | 35 |
US Patents: | 1 |
Tradenames: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 5 |
Clinical Trials: | 24 |
Patent Applications: | 239 |
DailyMed Link: | FLORBETABEN F-18 at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for FLORBETABEN F-18
Generic Entry Date for FLORBETABEN F-18*:
Constraining patent/regulatory exclusivity:
Dosage:
SOLUTION;INTRAVENOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for FLORBETABEN F-18
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
University of Pennsylvania | Phase 3 |
National Institutes of Health (NIH) | Phase 3 |
Life Molecular Imaging GmbH | Phase 3 |
Pharmacology for FLORBETABEN F-18
Drug Class | Radioactive Diagnostic Agent |
Mechanism of Action | Positron Emitting Activity |
US Patents and Regulatory Information for FLORBETABEN F-18
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Life Molecular | NEURACEQ | florbetaben f-18 | SOLUTION;INTRAVENOUS | 204677-001 | Mar 19, 2014 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for FLORBETABEN F-18
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
New Zealand | 555942 | Radiolabelled tilbene derivatives and their use for binding and imaging amyloid plaques | ⤷ Sign Up |
Israel | 183946 | STILBENE DERIVATIVES AND THEIR USE FOR BINDING AND IMAGING AMYLOID PLAQUES | ⤷ Sign Up |
Slovenia | 2213652 | ⤷ Sign Up | |
Eurasian Patent Organization | 200701299 | ПРОИЗВОДНЫЕ СТИЛЬБЕНА И ИХ ПРИМЕНЕНИЕ ДЛЯ СВЯЗЫВАНИЯ И ВИЗУАЛИЗАЦИИ АМИЛОИДНЫХ БЛЯШЕК | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for FLORBETABEN F-18
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2213652 | 122015000018 | Germany | ⤷ Sign Up | PRODUCT NAME: FLORBETABEN (18F); REGISTRATION NO/DATE: EU/1/13/906/001 20140220 |
2213652 | 504 | Finland | ⤷ Sign Up | |
2213652 | 1590005-3 | Sweden | ⤷ Sign Up | PRODUCT NAME: FLORBETABEN (18F); REG. NO/DATE: EU/1/13/906 20140224 |
2213652 | 132015902339134 | Italy | ⤷ Sign Up | PRODUCT NAME: FLORBETABEN (18)(NEURACEQ); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/13/906, 20140224 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.